CD274 and non-small cell lung carcinoma: Another published study by Chia-Wei et al. (2021) that analyses the cost-effectiveness of atezolizumab versus pembrolizumab as first-line monotherapy in patients with NSCLC and high PD-L1 expression has been found [44].